What is PlateletBio?
Founded in 2014, PlateletBio operates at the intersection of advanced cellular engineering and therapeutic development. The company specializes in a proprietary cell therapy platform designed to address complex medical challenges through innovative biological solutions. By focusing on the development of scalable, high-precision therapies, PlateletBio has established a distinct market presence, attracting significant interest from institutional investors who prioritize long-term value creation in the biotechnology space. Their operational model emphasizes the integration of cutting-edge science with scalable manufacturing processes, ensuring that their therapeutic candidates are positioned for clinical success and eventual commercialization.
How much funding has PlateletBio raised?
PlateletBio has raised a total of $75.5M across 1 funding round:
Series B
$75.5M
Series B (2021): $75.5M with participation from K2 HealthVentures, Ziff Capital Partners, Oxford Finance, SymBiosis, and Qiming Venture Partners
Key Investors in PlateletBio
K2 HealthVentures
K2 HealthVentures is an alternative investment firm providing flexible, long-term financing solutions to innovative companies within the life sciences and healthcare industries.
Oxford Finance
Oxford Finance is a specialty finance firm that offers tailored financial solutions and debt capital to healthcare and life sciences companies worldwide.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm focusing on innovative companies across technology and healthcare, providing strategic guidance and industry resources.
What's next for PlateletBio?
With the recent influx of capital, PlateletBio is poised to scale its operational infrastructure and advance its core pipeline through critical clinical development phases. The strategic focus will likely shift toward expanding its manufacturing capabilities and strengthening its intellectual property portfolio to maintain a competitive edge in the rapidly evolving cell therapy landscape. As the company matures, the emphasis will remain on achieving regulatory milestones and fostering strategic partnerships that enhance its market reach. This enterprise-level funding provides the necessary runway to navigate the complexities of the biotech sector, ensuring that PlateletBio remains at the forefront of medical innovation while delivering sustainable growth for its stakeholders.
See full PlateletBio company page
